Search Results

You are looking at 1 - 10 of 20 items for :

  • Willingness-to-Pay x
  • Clinical Medicine x
Clear All
Open access

Hristo P. Dobrev, Nikolay G. Atanasov and Donka D. Dimitrova

patients’ willingness to pay for dermatological and dental treatment. Journal of International Scientific Publications: Economy & Business 2013;7(2):219-28. 10. Drummond MF, O’Brien BJ, Stoddart GL, et al. [Methods for the economic evaluation of health care programs.] 2nd ed. Sofia: MF; 2007:289-94 (in Bulgarian). 11. McIntosh E, Clarke PM, Frew EJ, et al, eds. Applied methods of cost-benefit analysis in health care. Oxford: Oxford University Press; 2010:127-38. 12. Edejer TT, Baltussen R, Adam T, et al, editors. Making choices in health: WHO Guide to

Open access

Karmen Erjavec, Jožica Zajc, Melita Poler Kovačič, Jelka Šuštar Vozlič, Samo Uhan and Luka Juvančič

. Ljubljana: Biotehniška fakulteta, 2005. 9. ZPS. Javno mnenjska anketa o gensko spremenjenih organizmih. Ljubljana: Zveza potrošnikov Slovenije, 2007. 10. Boccaletti S, Moro D. Consumer willingness-to-pay for GM food products in Italy. AgBioForum 2000; 3: 259-267. 11. Allum N, Sturgis P, Tabourazi D, Brunton-Smith I. Science knowledge and attitudes across cultures: a meta-analysis. Public Underst Sci 2008; 17: 35-54. 12. Fischhoff B, Fischhoff I. Publics’ opinions about biotechnologies. AgBioForum 2001; 4: 155

Open access

Adawan Permpanich, Vithaya Kulsomboon and Kamol Udol

QALY and 256,199 THB per LYG ( Table 3 ). ICER/QALY and ICER/LYG reduced when the patients had MI at the older age, indicating that the addition of n-3 PUFAs is more cost-effective in elderly patients than in younger patients ( Figure 3 ). The probability of cost-effectiveness at different levels of willingness-to-pay in different ages of the patients is shown in Figure 4 . Figure 3 Incremental effectiveness of n-3 PUFAs supplementation at different ages of post-MI patients Figure 4 Cost-effectiveness acceptability curve of n-3 PUFAs

Open access

Teodor Pevec and Aleksandra Pisnik

, concluded that the connection is inconsistent, or the connection is either negative or positive. On the other hand, numerous researchers ( 51 , 52 ) have proposed that higher perceived prices lead to higher perceived service quality. Jensen’s study ( 53 ) showed that health service users are willing to pay more for higher quality services because they believe that higher prices mean higher quality. Tellis and Geath ( 54 ) also claimed that customers use prices as quality indicators. H7: The higher the perceived price of a health service, the higher its perceived

Open access

Milica Paut Kusturica, Ana Tomas, Zdenko Tomic, Dragica Bukumiric, Aleksandar Corac, Olga Horvat and Ana Sabo

analysis of where and why medications accumulate Environ Int 2008 34 1157 69 19 Abushanab AS, Sweileh WN, Wazaify M. Storage and wastage of drug products in Jordanian households: a cross-sectional survey. Int J Pharm Prac 2013; 21: 185-91. 10.1111/j.2042-7174.2012.00250.x Abushanab AS Sweileh WN Wazaify M Storage and wastage of drug products in Jordanian households: a cross-sectional survey Int J Pharm Prac 2013 21 185 91 20 Kotchen M, Kallaos J, Wheeler K, Wong C, Zahller M. Pharmaceuticals in wastewater: behaviour, preferences, and willingness to pay for a disposal

Open access

Zlatina I. Ivanova and Yavor Y. Ivanov

willingness to pay in asthma. Pharmacoeconomics 2002; 20(4): 257-65. 29. Castaldi P, Rogers W, Safran D, et al. Inhaler costs and medication nonadherence among seniors with chronic pulmonary disease. CHEST 2010; 138(3): 614-20. 30. Godard P, Chanez P, Siraudin L, et al. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J 2002; 19: 61-7. 31. Ayres J, Boyd R, Cowie H, et al. Costs of occupational asthma in the UK. Thorax 2011; 66: 128-33. 32. Kauppinen R, Sintonen H, Vilkka V, et al. Long-term (3-year) economic

Open access

Anja Radsel, Damjan Osredkar and David Neubauer

through neurodevelopmental paediatricians in regional outpatient clinics covering around 90% of Slovenian paediatric CP population. Out of original 150 children aged 8-16 years, randomly selected from the SRCP, contact data for 122 families were available; 91 caregivers (of 43 children aged 6-12 years and 48 adolescents aged 13-16 years) were willing to cooperate. Children with tested IQ score >70 or attending regular school were considered cognitively able to self-report, and 48 of them (26 children and 22 adolescents) agreed to do so. 2.2 The Procedure The

Open access

Christos Emmanouilides

, 12:993-980 [9] AGGRAWAL A. Affordability of cancer care in the UK-Is it time to introduce user changes? J Cancer Policy 2014, 2:31-39 [10] LANG HC. Willingness to pay for lung cancer treatment. Value in Health. Journal of the International Society for Pharmacoeconomics and Outcomes Research 2010, 13:743–749 [11] WONG YN, HAMILTON O, EGELSTON B, SALADOR K, MURPHY C, MEROPOL NJ. Understanding how out-of-pocket expenses, treatment value, and patient characteristics influence treatment choices. Oncologist 2010, 15:566–576 [12] CHEVREUL K

Open access

Gyöngyi Szabó Földesi

’s Report shows. Retrieved Aug 5, 2013, from http://www.huffingtonpost.com/2013/03/21/democracyindex-201... Voice of America. Reuters. (July 17, 2013). Brazilian Congress to Investigate Ballooning Word Cup Costs. Retrieved July 29, 2013, from http://www.voanews.com/content/reu-brazil-ballooning-world-cup-costs/1704141.html Whitson, D., Macintosh, D. (1996). The Global Circus: International Sport, Tourism and the Marketing of Global Cities. Journal of Sport and Social Issues, 20, 278-295.

Open access

Yuwadee Leelukkanaveer, Pornchai Sithisarankul and Narin Hirunsutthikul

:464-9. 8. Ormaasen V, Sandvik L, Dudman SG, Bruun JN. HIV related and non-HIV related mortality before and after the introduction of highly active antiretroviral therapy (HAART) in Norway compared to the general population. Scand J Infect Dis. 2007; 39:51-7. 9. Garcia F, de Lazzari E, Plana M, Castro P, Mestre G, Nomdedeu M, et al. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr. 2004; 36:702-13. 10. Egger M, May M, Chene G, Phillips AN, Ledergerber